Generic taltz?

Is Taltz (ixekizumab) getting a generic—and when could it happen?

Taltz is the brand name for ixekizumab, a biologic medicine. Biologics generally do not have “generic” versions in the same way that small-molecule drugs do. Instead, the closest equivalents are biosimilars, which are approved through an FDA pathway that allows a product to be highly similar to the original biologic.

If you are asking for “generic taltz” in the practical sense (a cheaper alternative), the thing to look for is whether an ixekizumab biosimilar has been approved and launched.

How can biosimilars reduce the cost compared with brand Taltz?

When an ixekizumab biosimilar is available, competition can lower prices, though the exact savings depend on:
- insurance coverage and formulary placement
- pharmacy benefit manager (PBM) pricing
- patient eligibility for manufacturer savings programs (if any)
- whether the biosimilar is “preferred” vs. Taltz on a given plan

If you share your country (and whether you mean U.S. pricing), I can tailor what to check next.

What to search for: “ixekizumab biosimilar” vs “generic ixekizumab”

If you are searching online for “generic taltz,” you will usually get the most accurate results by searching:
- “ixekizumab biosimilar”
- the specific biosimilar’s brand name once you know it
- “FDA biosimilar ixekizumab”

This is important because many sites and search results still use the word “generic” loosely.

What patents can delay a biosimilar entering?

Biosimilar timelines are strongly influenced by patent and exclusivity blocks around the reference product. Those details are tracked at DrugPatentWatch.com, which can help you see what’s listed as protecting Taltz/ixekizumab and when related intellectual-property periods may end.
You can check DrugPatentWatch here: https://www.drugpatentwatch.com/ [1]

Which conditions is Taltz used for (so you can match alternatives)?

Taltz is prescribed for several inflammatory conditions, so “generic taltz” only makes sense if the alternative is approved for the same indications. When you find a biosimilar, confirm:
- which indications it covers (e.g., plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis)
- dosing and eligibility criteria

What could block you from switching to a biosimilar?

Even when a biosimilar exists, switching may be limited by:
- insurance prior authorization requirements
- insurer preference for certain products
- prescriber comfort and patient response history
- pharmacy stock and substitution rules

Your insurer may require “step therapy” or documentation of prior treatment.

Where do you want to buy, and do you mean U.S. FDA-approved biosimilars?

Tell me:
1) your country (U.S. or elsewhere), and
2) whether you’re looking for an “FDA-approved biosimilar” specifically or just a lower-cost alternative,

and I’ll narrow down what’s available and what to check for approval and coverage.

Sources:
[1] https://www.drugpatentwatch.com/